NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Rifaximin for maintaining remission from episodes of hepatic encephalopathy

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

1.	Have any potential equality issues been identified during the scoping
	process (draft scope consultation and scoping workshop discussion),
	and, if so, what are they?

No

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Not applicable

3. Has any change to the draft scope been agreed to highlight potential equality issues?

Not applicable

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No

Technology appraisals: Scoping Equality impact assessment for the single technology appraisal of Rifaximin for maintaining remission from episodes of hepatic encephalopathy Issue date: December 2012

Approved by Associate Director (name): Helen Knight

Date: 07/12/2012